Kite Pharma Completes $35m Financing
Kite Pharma, a clinical stage biotechnology company focused on developing innovative targeted immunotherapies for cancer, has closed a $20 million private placement of shares of its Series A Preferred Stock. Joined by a new investor, Alta Partners, all existing major investors participated in the financing.
16 May 2013•3 mins read
